Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B McInnes

Showing results (361-370 of 537) with videos related to

Pageof 54
Sort By:
Annals of the Rheumatic Diseases|December 26, 2013
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled studyIain B McInnes, Liz Thompson, Jon T Giles, et al.
Annals of the Rheumatic Diseases|May 29, 2021
Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasisKeith Colaco, Ker-Ai Lee, Shadi Akhtari, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2022
Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort StudyKeith Colaco, Ker-Ai Lee, Shadi Akhtari, et al.
The Lancet. Rheumatology|January 25, 2024
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Alan J Kivitz, et al.
Immunology and Cell Biology|October 29, 2014
The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigensChris A H Hansell, Lindsay M MacLellan, Rachel S Oldham, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
Annals of the Rheumatic Diseases|February 26, 2013
The liver X receptor pathway is highly upregulated in rheumatoid arthritis synovial macrophages and potentiates TLR-driven cytokine releaseDarren Lee Asquith, Lucy E Ballantine, Jagtar Singh Nijjar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 4, 2014
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinibChristina Charles-Schoeman, Roy Fleischmann, Jean Davignon, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2021
Translational targeting of inflammation and fibrosis in frozen shoulder: Molecular dissection of the T cell/IL-17A axisMoeed Akbar, Lindsay A N Crowe, Michael McLean, et al.
Pageof 54

Showing results (361-370 of 537) with videos related to

Sort By:
Pageof 54
Annals of the Rheumatic Diseases|December 26, 2013
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled studyIain B McInnes, Liz Thompson, Jon T Giles, et al.
Annals of the Rheumatic Diseases|May 29, 2021
Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasisKeith Colaco, Ker-Ai Lee, Shadi Akhtari, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2022
Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort StudyKeith Colaco, Ker-Ai Lee, Shadi Akhtari, et al.
The Lancet. Rheumatology|January 25, 2024
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Alan J Kivitz, et al.
Immunology and Cell Biology|October 29, 2014
The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigensChris A H Hansell, Lindsay M MacLellan, Rachel S Oldham, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
Annals of the Rheumatic Diseases|February 26, 2013
The liver X receptor pathway is highly upregulated in rheumatoid arthritis synovial macrophages and potentiates TLR-driven cytokine releaseDarren Lee Asquith, Lucy E Ballantine, Jagtar Singh Nijjar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 4, 2014
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinibChristina Charles-Schoeman, Roy Fleischmann, Jean Davignon, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2021
Translational targeting of inflammation and fibrosis in frozen shoulder: Molecular dissection of the T cell/IL-17A axisMoeed Akbar, Lindsay A N Crowe, Michael McLean, et al.
Pageof 54